1Molina J R,Yang P,Cassivi S D. Non-small cell lung cancer:epidemiology,risk factors,treatment,and survivorship[J].Mayo Clinic Proceedings,2008,(05):84.
2Pfister D G,Johnson D H,Azzoli C G. American society of clinical oncology unresectable non-small-cell lung cancer guideline:update 2003[J].Clinical Oncology,2004,(02):30.
5Thatcher N,Chang A,Parikh P. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomized,placebo-controlled,multicentre study(iressa survival evaluation in lung cancer)[J].LANCET,2005,(9496):527.
9Park K,Goto K. A Review of the benefit-risk profile of gefitinib in Asian patient with advance non-small-cell lung cancer[J].CURRENT MEDICAL RESEARCH AND OPINION,2006,(03):561.
4[1]Gatzemeier U,Groth G,Butts C,et al.Randomized phase Ⅱ trial of gemcitabine-cisplatin with or without trastuzumab in HER-2-positive non-small cell lung cancer.Ann Oncol,2004,15:3
5[2]Villalona-Calero MA,Ritch P,Figueroa JA,et al.A phase Ⅰ/Ⅱ study of LY900003,an antisense inhibitor kinase C-alpha,in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.Clin Cancer Res,2004,10:6086
6[3]Paz-Ares L,Douillard J Y,Koralewski P,et al.Phase Ⅲ study of gemcitabine and cisplatin with or without aprinocarsen,a protein kinase C-alpha antisense oligonucleotide in patients with advanced-stage non-small cell lung cancer.J Clin Oncol,2006,20:1428
7[4]Altorki NK,Keresztes RS,Port JL,et al.Celecoxib,a selective cyclo-oxygenase-2 inhibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer.J Clin Oncol,2003,21 (14):2645
8[5]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer.J Clin Oncol,2003,21:223746
9[6]Kris MG,Natsle RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:A randomized trial.JAMA,2003,290:214958
10[7]Perez-Soler R,Chachou A,Huberman M,et al.A Phase Ⅱ trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774,following platinum-based chemotherapy,in patients with advanced,EGFR-expressing,nonsmall cell lung cancer.Proc Am Soc Clin Oncol,2001,1235A
